Core Points - NuGen Medical Devices has announced that its EziAutoJector® product line has received NHS Drug Tariff approval in the UK, allowing diabetes patients to access the device at no cost as part of NHS-funded care [1][2][6] - The approval aligns with NICE guidelines, promoting personalized patient choice in insulin delivery methods, and ensures pharmacists are reimbursed for dispensing the product [2][6] - EziAutoJector® Ltd has established distribution channels through a major pharmaceutical wholesaler, targeting both high-street pharmacies and online pharmacy services [3] - A direct-to-consumer e-commerce channel will enhance accessibility for patients facing prescribing restrictions [4] - Transitioning to EziAutoJector® allows patients to eliminate the use of over 1,000 single-use insulin needles annually, reducing biohazardous waste and supporting NHS environmental goals [5][6] Company Overview - NuGen Medical Devices specializes in needle-free drug delivery technology, with its flagship InsuJet™ system approved in 42 countries [6]